Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint

Lunai Bioworks updated only the hyperlink location for its Second Amended Complaint, leaving all prior release statements unchanged.

Rhea-AI Summary

Lunai Bioworks (LNAI) issued a correction on September 4, 2026 to its August 27, 2026 press release related to a Second Amended Complaint.

The only change is an updated hyperlink specifying where the Second Amended Complaint is available. All other statements in the original release remain accurate and unchanged, and no new information is being disclosed. The complaint can now be accessed via Lunai Bioworks’ investor relations website or directly through the court’s public docket.

Market Context

The August 4 collaboration announcement coincided with a 6.69% 24-hour gain, a useful historical com...

Analysis

The August 4 collaboration announcement coincided with a 6.69% 24-hour gain, a useful historical comparator. This notice only corrects a link; the key risk is that it provides no additional information about the complaint.

Key Figures

Broker-dealers named: Six broker-dealers Original release date: August 27, 2026 Civil action number: 26-549-CFC

3 metrics

Broker-dealers named Six broker-dealers Original August 27, 2026 release referenced in correction

Original release date August 27, 2026 Date of the release being corrected

Civil action number 26-549-CFC Second Amended Complaint filed in the U.S. District Court for Delaware

Historical Context

5 past events · Latest: Aug 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 27	Legal complaint expansion	Neutral	-2.1%	Company named six broker-dealers in an expanded naked short-selling lawsuit
Aug 4	Collaboration agreement	Positive	+6.7%	Company signed a definitive collaboration agreement targeting Parkinson's disease data
Aug 4	Lawsuit defendants named	Neutral	+6.7%	Company identified ten defendants in a naked short-selling fraud suit
Jun 17	Shareholder letter	Positive	+40.6%	CEO outlined biodefense, neurology, contract, grant, and compliance developments
May 28	AI discovery collaboration	Positive	+16.0%	Companies launched a foundation-funded Parkinson's and rare epilepsy collaboration

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were mixed: collaboration-related announcements rose 6.69%, 16.03%, and 40.6%, while lawsuit-related announcements moved -2.08% and +6.69%.

Key Terms

broker-dealers, naked short selling

2 terms

broker-dealers financial

"Names Six Broker-Dealers in Expanded Naked Short Selling Suit"

A broker-dealer is a firm or individual that helps people buy and sell securities and may also trade those securities for its own account. Think of it like a market clerk who can either match a buyer with a seller or sell items from the shop’s shelves; investors rely on broker-dealers to execute trades, custody assets, provide market access and advice, and their actions and fees can affect trade speed, cost and potential conflicts of interest.

naked short selling financial

"Names Six Broker-Dealers in Expanded Naked Short Selling Suit"

Naked short selling is selling shares you do not own and have not borrowed or reserved to deliver to the buyer, unlike ordinary short selling where the seller first borrows the shares. Think of it as promising to sell a car you haven’t secured from a lender or owner; if the seller can’t deliver, it can artificially increase the number of shares trading, push the price down, and raise risks for investors and for the company’s market stability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Correction Updates a Reference Link; No Other Content in the Original Release Has Changed

WILMINGTON, Del. and SACRAMENTO, Calif., Sept. 4, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) ("Lunai" or the "Company") today issued this correction to the press release the Company distributed on August 27, 2026 under the headline "Lunai Bioworks (NASDAQ: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit." The sole correction is to the hyperlink identifying where a copy of the Company's Second Amended Complaint can be found. No other statement in the original release has changed, and the Company is not disclosing any new information in this correction.

A copy of the Second Amended Complaint, filed in the U.S. District Court for the District of Delaware (Civil Action No. 26-549-CFC), is available on the Investor Relations section of the Company's website at https://s201.q4cdn.com/863337820/files/doc_news/2026/Aug/27/attachments/Complaint-SecondAmendedRedacted-ECF037-082826-C.pdf or directly through the court's public docket.

All other statements in the original release, issued August 27, 2026, remain accurate and unchanged.

About Lunai Bioworks

Lunai Bioworks, Inc. (NASDAQ: LNAI) is a biology-first drug discovery company decoding the molecular underpinnings of central nervous system disease. Its Augusta AI platform begins with real human patient data, not cell lines or chemistry, to identify disease sub-populations, trace altered genes to candidate compounds, and validate drug candidates in vivo using CRISPR-induced zebrafish models and proprietary machine vision. Lunai's pipeline targets Alzheimer's disease, Parkinson's disease, epilepsy, and alcohol use disorder. Through its BioSymetrics platform, Lunai also operates an AI-powered biodefense program applying its drug discovery platform in reverse to identify chemical threats and develop countermeasures. Lunai Bioworks was formed through the April 2025 merger of Renovaro Inc. and BioSymetrics, Inc. and is headquartered in California. For more information, visit www.biosymetrics.com.

Forward-Looking Statements

This release contains forward-looking statements, including statements regarding pending litigation, within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties, including those related to the outcome of litigation, that could cause actual results to differ materially. Lunai undertakes no obligation to update these statements except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-nasdaq-lnai-issues-correction-to-press-release-regarding-second-amended-complaint-302870048.html

SOURCE Lunai Bioworks Inc.

FAQ

What did Lunai Bioworks (LNAI) correct in its September 4, 2026 press release?

Lunai Bioworks corrected only the hyperlink that identifies where a copy of its Second Amended Complaint can be found. The company stated that no other content from the August 27, 2026 release has changed and that no new information is being disclosed.

Where can investors find Lunai Bioworks’ Second Amended Complaint mentioned in the LNAI correction?

The Second Amended Complaint is available on Lunai Bioworks’ Investor Relations section of its website via the updated link, or directly through the U.S. District Court for the District of Delaware public docket under Civil Action No. 26-549-CFC.

Did Lunai Bioworks change any statements from its August 27, 2026 LNAI press release?

No. Lunai Bioworks stated that all other statements in the original August 27, 2026 press release remain accurate and unchanged. The sole adjustment in the September 4, 2026 correction is the updated hyperlink to the Second Amended Complaint.